A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

Recruiting now · Phase 3

Conditions studied: Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

In brief

This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

Key facts

Study ID

NCT07081997

Run by

Ascendis Pharma Bone Diseases A/S

People needed

36

Starts

2026-05-07

Expected to finish

2028-06-01

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females, ≥18 years of age at the time of providing informed consent
• Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks
• Receiving doses of palopegteriparatide at or above 30 µg/day
• For individuals receiving 30 µg/day: evidence that dose is insufficient to keep serum calcium in the normal range, defined as:
• Documented hypocalcemia within 12 weeks prior to Screening; and/or Standing dose of calcitriol ≥0.25 μg/day, and / or (elemental) calcium ≥1500 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening
• For individuals receiving 33 µg/day or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium
• Confirmation of laboratory parameters (Central or Local) within 2 weeks of screening visit and prior to randomization:
• 25(OH) vitamin D levels of ≥ 20 ng/mL (≥49 nmol/L) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg/dL (≥0.53 mmol/L) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range
• Albumin-adjusted sCa 7.8 - 10.6 mg/dL (or 1.95 - 2.64 mmol/L)
• Ionized sCa 4.40 - 5.29 mg/dL (1.10 - 1.32 mmol/L)
• BMI 17- 40 kg/m2 at Screening
• If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand
• eGFR ≥30 mL/min/1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula

You may not qualify if…

• Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
• Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP
• Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin >30 µg/day, or systemic corticosteroids (other than as replacement therapy)
• Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1
• Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an investigational trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening
• Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening
• Use of denosumab or romosozumab within 2 years prior to Screening. Use of raloxifene within 4 weeks prior to Screening.
• Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening.
• Increased risk for osteosarcoma
• Women who are pregnant, intend to become pregnant, or are lactating
• Diagnosed drug or alcohol dependence within 3 years prior to Screening
• Chronic or severe cardiac disease within 26 weeks prior to Screening
• Cerebrovascular accident within 5 years prior to Screening.
• Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout
• Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening.
• Known allergy or sensitivity to PTH or any of the excipients [metacresol, mannitol, succinic acid, NaOH/(HCl)] of the investigational product

Where it is running

• Ascendis Pharma Investigational Site — Reno, Nevada, United States (enrolling)
• Ascendis Pharma Investigational Site — New York, New York, United States (enrolling)
• Ascendis Pharma Investigational Site — Spokane Valley, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.